Literature DB >> 22265408

Correction of both NBD1 energetics and domain interface is required to restore ΔF508 CFTR folding and function.

Wael M Rabeh1, Florian Bossard, Haijin Xu, Tsukasa Okiyoneda, Miklos Bagdany, Cory M Mulvihill, Kai Du, Salvatore di Bernardo, Yuhong Liu, Lars Konermann, Ariel Roldan, Gergely L Lukacs.   

Abstract

The folding and misfolding mechanism of multidomain proteins remains poorly understood. Although thermodynamic instability of the first nucleotide-binding domain (NBD1) of ΔF508 CFTR (cystic fibrosis transmembrane conductance regulator) partly accounts for the mutant channel degradation in the endoplasmic reticulum and is considered as a drug target in cystic fibrosis, the link between NBD1 and CFTR misfolding remains unclear. Here, we show that ΔF508 destabilizes NBD1 both thermodynamically and kinetically, but correction of either defect alone is insufficient to restore ΔF508 CFTR biogenesis. Instead, both ΔF508-NBD1 energetic and the NBD1-MSD2 (membrane-spanning domain 2) interface stabilization are required for wild-type-like folding, processing, and transport function, suggesting a synergistic role of NBD1 energetics and topology in CFTR-coupled domain assembly. Identification of distinct structural deficiencies may explain the limited success of ΔF508 CFTR corrector molecules and suggests structure-based combination corrector therapies. These results may serve as a framework for understanding the mechanism of interface mutation in multidomain membrane proteins.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22265408      PMCID: PMC3431169          DOI: 10.1016/j.cell.2011.11.024

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  57 in total

1.  Evaluation of fluorescence-based thermal shift assays for hit identification in drug discovery.

Authors:  Mei-Chu Lo; Ann Aulabaugh; Guixian Jin; Rebecca Cowling; Jonathan Bard; Michael Malamas; George Ellestad
Journal:  Anal Biochem       Date:  2004-09-01       Impact factor: 3.365

Review 2.  Pharmacological chaperones: potential treatment for conformational diseases.

Authors:  Virginie Bernier; Monique Lagacé; Daniel G Bichet; Michel Bouvier
Journal:  Trends Endocrinol Metab       Date:  2004-07       Impact factor: 12.015

3.  Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis.

Authors:  S H Cheng; R J Gregory; J Marshall; S Paul; D W Souza; G A White; C R O'Riordan; A E Smith
Journal:  Cell       Date:  1990-11-16       Impact factor: 41.582

4.  Identification of revertants for the cystic fibrosis delta F508 mutation using STE6-CFTR chimeras in yeast.

Authors:  J L Teem; H A Berger; L S Ostedgaard; D P Rich; L C Tsui; M J Welsh
Journal:  Cell       Date:  1993-04-23       Impact factor: 41.582

5.  Altered chloride ion channel kinetics associated with the delta F508 cystic fibrosis mutation.

Authors:  W Dalemans; P Barbry; G Champigny; S Jallat; K Dott; D Dreyer; R G Crystal; A Pavirani; J P Lecocq; M Lazdunski
Journal:  Nature       Date:  1991 Dec 19-26       Impact factor: 49.962

6.  Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation.

Authors:  J P Clancy; Steven M Rowe; Frank J Accurso; Moira L Aitken; Raouf S Amin; Melissa A Ashlock; Manfred Ballmann; Michael P Boyle; Inez Bronsveld; Preston W Campbell; Kris De Boeck; Scott H Donaldson; Henry L Dorkin; Jordan M Dunitz; Peter R Durie; Manu Jain; Anissa Leonard; Karen S McCoy; Richard B Moss; Joseph M Pilewski; Daniel B Rosenbluth; Ronald C Rubenstein; Michael S Schechter; Martyn Botfield; Claudia L Ordoñez; George T Spencer-Green; Laurent Vernillet; Steve Wisseh; Karl Yen; Michael W Konstan
Journal:  Thorax       Date:  2011-08-08       Impact factor: 9.139

7.  The Hsc70 co-chaperone CHIP targets immature CFTR for proteasomal degradation.

Authors:  G C Meacham; C Patterson; W Zhang; J M Younger; D M Cyr
Journal:  Nat Cell Biol       Date:  2001-01       Impact factor: 28.824

8.  Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive.

Authors:  G M Denning; M P Anderson; J F Amara; J Marshall; A E Smith; M J Welsh
Journal:  Nature       Date:  1992-08-27       Impact factor: 49.962

9.  Glycerol reverses the misfolding phenotype of the most common cystic fibrosis mutation.

Authors:  S Sato; C L Ward; M E Krouse; J J Wine; R R Kopito
Journal:  J Biol Chem       Date:  1996-01-12       Impact factor: 5.157

10.  Alteration of the cystic fibrosis transmembrane conductance regulator folding pathway.

Authors:  B H Qu; P J Thomas
Journal:  J Biol Chem       Date:  1996-03-29       Impact factor: 5.157

View more
  133 in total

1.  Thermal instability of ΔF508 cystic fibrosis transmembrane conductance regulator (CFTR) channel function: protection by single suppressor mutations and inhibiting channel activity.

Authors:  Xuehong Liu; Nicolette O'Donnell; Allison Landstrom; William R Skach; David C Dawson
Journal:  Biochemistry       Date:  2012-06-15       Impact factor: 3.162

Review 2.  hERG quality control and the long QT syndrome.

Authors:  Brian Foo; Brittany Williamson; Jason C Young; Gergely Lukacs; Alvin Shrier
Journal:  J Physiol       Date:  2016-02-09       Impact factor: 5.182

3.  Using a second-order differential model to fit data without baselines in protein isothermal chemical denaturation.

Authors:  Chuanning Tang; Scott Lew; Dacheng He
Journal:  Protein Sci       Date:  2016-02-11       Impact factor: 6.725

4.  Partial rescue of F508del-cystic fibrosis transmembrane conductance regulator channel gating with modest improvement of protein processing, but not stability, by a dual-acting small molecule.

Authors:  Jia Liu; Hermann Bihler; Carlos M Farinha; Nikhil T Awatade; Ana M Romão; Dayna Mercadante; Yi Cheng; Isaac Musisi; Walailak Jantarajit; Yiting Wang; Zhiwei Cai; Margarida D Amaral; Martin Mense; David N Sheppard
Journal:  Br J Pharmacol       Date:  2018-02-22       Impact factor: 8.739

5.  The endosomal trafficking factors CORVET and ESCRT suppress plasma membrane residence of the renal outer medullary potassium channel (ROMK).

Authors:  Timothy D Mackie; Bo-Young Kim; Arohan R Subramanya; Daniel J Bain; Allyson F O'Donnell; Paul A Welling; Jeffrey L Brodsky
Journal:  J Biol Chem       Date:  2018-01-08       Impact factor: 5.157

6.  Analysis of cystic fibrosis-associated P67L CFTR illustrates barriers to personalized therapeutics for orphan diseases.

Authors:  Carleen M Sabusap; Wei Wang; Carmel M McNicholas; W Joon Chung; Lianwu Fu; Hui Wen; Marina Mazur; Kevin L Kirk; James F Collawn; Jeong S Hong; Eric J Sorscher
Journal:  JCI Insight       Date:  2016-09-08

Review 7.  Ion Channel Modulators in Cystic Fibrosis.

Authors:  Martina Gentzsch; Marcus A Mall
Journal:  Chest       Date:  2018-05-08       Impact factor: 9.410

8.  Impact of the F508del mutation on ovine CFTR, a Cl- channel with enhanced conductance and ATP-dependent gating.

Authors:  Zhiwei Cai; Timea Palmai-Pallag; Pissared Khuituan; Michael J Mutolo; Clément Boinot; Beihui Liu; Toby S Scott-Ward; Isabelle Callebaut; Ann Harris; David N Sheppard
Journal:  J Physiol       Date:  2015-04-09       Impact factor: 5.182

9.  Gout-causing Q141K mutation in ABCG2 leads to instability of the nucleotide-binding domain and can be corrected with small molecules.

Authors:  Owen M Woodward; Deepali N Tukaye; Jinming Cui; Patrick Greenwell; Leeza M Constantoulakis; Benjamin S Parker; Anjana Rao; Michael Köttgen; Peter C Maloney; William B Guggino
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-14       Impact factor: 11.205

10.  Combination potentiator ('co-potentiator') therapy for CF caused by CFTR mutants, including N1303K, that are poorly responsive to single potentiators.

Authors:  Puay-Wah Phuan; Jung-Ho Son; Joseph-Anthony Tan; Clarabella Li; Ilaria Musante; Lorna Zlock; Dennis W Nielson; Walter E Finkbeiner; Mark J Kurth; Luis J Galietta; Peter M Haggie; Alan S Verkman
Journal:  J Cyst Fibros       Date:  2018-06-12       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.